Long-term Ab exposure augments mCa2+-independent mROSmediated depletion of cardiolipin for the shift of a lethal transient mitochondrial permeability transition to its permanent mode in NARP cybrids: A protective targeting of melatonin

Journal of Pineal Research

Volumn 54, Issue 1, 2013, Pages 107-125

  Hsiao, Chia Wei ^a   Peng, Tsung I ^b,c   Peng, Alexander C ^d   Reiter, Russel J ^e   Tanaka, Masashi ^f   Lai, Yiu Kay ^a   Jou, Mei Jie ^g  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d Williston Northampton School   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Amyloid peptide; Ataxia and retinitis pigmentosa cybrids; Cardiolipin; MCa2+; Melatonin; Mitochondrial reactive oxygen species; Neurological muscle weakness; Transient MPT

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM ION; CARDIOLIPIN; MELATONIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; CALCIUM; CARRIER PROTEIN; MITOCHONDRIAL REACTIVE OXYGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CELL VIABILITY; DEPOLARIZATION; HUMAN; HUMAN CELL; LASER MICROSCOPY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NEUROLOGIC DISEASE; NEUROLOGICAL MUSCLE WEAKNESS ATAXIA AND RETINITIS PIGMENTOSA; OSTEOSARCOMA; OXYGEN CONSUMPTION; RISK FACTOR; AMYLOID Β-PEPTIDE; DRUG EFFECT; MCA2+; METABOLISM; MITOCHONDRIAL MYOPATHY; MITOCHONDRION; NEUROLOGICAL MUSCLE WEAKNESS, ATAXIA, AND RETINITIS PIGMENTOSA CYBRIDS; RETINITIS PIGMENTOSA; TRANSIENT-MPT;

AMYLOID Β-PEPTIDE; CARDIOLIPIN; MCA2+; MELATONIN; MITOCHONDRIAL REACTIVE OXYGEN SPECIES; NEUROLOGICAL MUSCLE WEAKNESS, ATAXIA, AND RETINITIS PIGMENTOSA CYBRIDS; TRANSIENT-MPT;

AMYLOID BETA-PEPTIDES; CALCIUM; CARDIOLIPINS; HUMANS; MELATONIN; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MITOCHONDRIAL MYOPATHIES; REACTIVE OXYGEN SPECIES; RETINITIS PIGMENTOSA;

EID: 84872694511     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12004     Document Type: Article

References (95)

1. HAASS C, SELKOE DJ. Soluble protein oligomers in neurode-generation: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8:101-112.
2. ROSALES-CORRAL SA, ACUNA-CASTROVIEJO D, COTO-MONTES A et al. Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J Pineal Res 2012; 52:167-202.
3. REDDY PH, MCWEENEY S. Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol Aging 2006; 27:1060-1077.
4. SAUNDERS AM, STRITTMATTER WJ, SCHMECHEL D et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43:1467-1472.
5. ROGAEVA E, MENG Y, LEE JH et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007; 39:168-177.
6. MOREIRA PI, SANTOS MS, OLIVEIRA CR. Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid Redox Signal 2007; 9:1621-1630.
7. MANCUSO M, COPPEDE F, MURRI L, SICILIANO G. Mitochondrial cascade hypothesis of Alzheimer's disease: myth or reality? Antioxid Redox Signal 2007; 9:1631-1646.
8. REDDY PH. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid Redox Signal 2007; 9:1647-1658.
9. LEUNER K, HAUPTMANN S, ABDEL-KADER R et al. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal 2007; 9:1659-1675.
10. PAGANI L, ECKERT. A amyloid-beta interaction with mitochondria. Int J Alzheimers Dis 2011; 2011:925050.
11. TILLEMENT L, LECANU L, PAPADOPOULOS V. Alzheimer's disease: effects of beta-amyloid on mitochondria. Mitochondrion 2011; 11:13-21.
12. RHEIN V, SONG X, WIESNER A et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 2009; 106:20057-20062.
13. ECKERT A, HAUPTMANN S, SCHERPING I et al. Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) 2008; 86:1255-1267.
14. HAUPTMANN S, SCHERPING I, DROSE S et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 2009; 30:1574-1586.
15. LUSTBADER JW, CIRILLI M, LIN C et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004; 304:448-452.
16. GLABE CG, KAYED R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 2006; 66:S74-S78.
17. REDDY PH, BEAL MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 2008; 14:45-53.
18. ALIKHANI N, ANKARCRONA M, GLASER E. Mitochondria and Alzheimer's disease: amyloid-beta peptide uptake and degradation by the presequence protease, hPreP. J Bioenerg Biomembr 2009; 41:447-451.
19. HANSSON PETERSEN CA, ALIKHANI N, BEHBAHANI H et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 2008; 105:13145-13150.
20. DEVI L, RAGHAVENDRAN V, PRABHU BM, AVADHANI NG, ANANDATHEERTHAVARADA HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008; 283:9089-9100.
21. HIRAI K, ALIEV G, NUNOMURA A et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001; 21:3017-3023.
22. TILLEMENT L, LECANU L, YAO W, GREESON J, PAPADOPOULOS V. The spirostenol (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate blocks mitochondrial uptake of Abeta in neuronal cells and prevents Abeta-induced impairment of mitochondrial function. Steroids 2006; 71:725-735.
23. CANEVARI L, CLARK JB, BATES TE. Beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett 1999; 457:131-134.
24. TAKUMA K, YAO J, HUANG J et al. ABAD enhances A beta-induced cell stress via mitochondrial dysfunction. FASEB J 2005; 19:597-598.
25. MERATAN AA, GHASEMI A, NEMAT-GORGANI M. Membrane integrity and amyloid cytotoxicity: a model study involving mitochondria and lysozyme fibrillation products. J Mol Biol 2011; 409:826-838.
26. DRAGICEVIC N, COPES N, O'NEAL-MOFFITT G et al. Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res 2011; 51:75-86.
27. BEAL MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000; 23:298-304.
28. LIN MT, BEAL MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443:787-795.
29. SCHON EA, PRZEDBORSKI S. Mitochondria: the next (neurode) generation. Neuron 2011; 70:1033-1053.
30. 2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE 2008; 3:e2718.
31. 2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010; 47:264-272.
32. 2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF. Antioxid Redox Signal 2011; 14:1209-1223.
33. TOESCU EC, VERKHRATSKY A. The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell 2007; 6:267-273.
34. MATTSON MP, GLEICHMANN M, CHENG A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008; 60:748-766.
35. CAMANDOLA S, MATTSON MP. Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. Biochim Biophys Acta 2011; 1813:965-973.
36. GLEICHMANN M, MATTSON MP. Neuronal calcium homeostasis and dysregulation. Antioxid Redox Signal 2011; 14:1261-1273.
37. DEMURO A, PARKER I, STUTZMANN GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 2010; 285:12463-12468.
38. SHEEHAN JP, SWERDLOW RH, MILLER SW et al. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 1997; 17:4612-4622.
39. PARK J, LEE J, CHOI C. Mitochondrial network determines intracellular ROS dynamics and sensitivity to oxidative stress through switching inter-mitochondrial messengers. PLoS ONE 2011; 6:e23211.
40. HE Y, CUI J, LEE JC et al. Prolonged exposure of cortical neurons to oligomeric amyloid-beta impairs NMDA receptor function via NADPH oxidase-mediated ROS production: protective effect of green tea (-)-epigallocatechin-3-gallate. ASN Neuro 2011; 3:e00050.
41. De FELICE FG, VELASCO PT, LAMBERT MP et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007; 282: 11590-11601.
42. MOREIRA PI, SANTOS MS, MORENO A, OLIVEIRA C. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci Rep 2001; 21:789-800.
43. MOREIRA PI, SANTOS MS, MORENO A, REGO AC, OLIVEIRA C. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J Neurosci Res 2002; 69:257-267.
44. CLEMENTI ME, MARINI S, COLETTA M, ORSINI F, GIARDINA B, MISITI F. Abeta (31-35) and Abeta (25-35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: role of the redox state of methionine-35. FEBS Lett 2005; 579:2913-2918.
45. KIM HS, LEE JH, LEE JP et al. Amyloid beta peptide induces cytochrome C release from isolated mitochondria. NeuroReport 2002; 13:1989-1993.
46. REDDY PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 2009; 218:286-292.
47. DU H, GUO L, FANG F et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 2008; 14:1097-1105.
48. DU H, YAN SS. Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta. Biochim Biophys Acta 2010; 1802:198-204.
49. JOU MJ, PENG TI, YU PZ et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res 2007; 43:389-403.
50. 2+, and lipid insults in NARP cybrids: a potential therapeutic target for melatonin. J Pineal Res 2012; 52:93-106.
51. 2+ stress in astrocyte. J Pineal Res 2011; 50:427-435.
52. 2+- mediated permeability transition and beyond in rat brain astrocytes. J Pineal Res 2010; 48: 20-38.
53. LIN MT, SIMON DK, AHN CH, KIM LM, BEAL MF. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet 2002; 11:133-145.
54. ONYANGO I, KHAN S, MILLER B, SWERDLOW R, TRIMMER P, BENNETT P Jr. Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's disease. Int J Alzheimers Dis 2006; 9:183-193.
55. REDDY PH, BEAL MF. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev 2005; 49:618-632.
56. COSKUN PE, BEAL MF, WALLACE DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 2004; 101:10726-10731.
57. SWERDLOW RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res 2007; 85:3416-3428.
58. PARK CB, LARSSON NG. Mitochondrial DNA mutations in disease and aging. J Cell Biol 2011; 193:809-818.
59. MAO P, REDDY PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. Biochim Biophys Acta 2011; 1812:1359-1370.
60. CORRAL-DEBRINSKI M, HORTON T, LOTT MT et al. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 1994; 23:471-476.
61. SHOFFNER JM, BROWN MD, TORRONI A et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 1993; 17:171-184.
62. CARDOSO SM, SANTANA I, SWERDLOW RH, OLIVEIRA CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 2004; 89:1417-1426.
63. KHAN SM, CASSARINO DS, ABRAMOVA NN et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol 2000; 48:148-155.
64. ONYANGO IG, BENNETT JP Jr, TUTTLE JB. Endogenous oxidative stress in sporadic Alzheimer's disease neuronal cybrids reduces viability by increasing apoptosis through pro-death signaling pathways and is mimicked by oxidant exposure of control cybrids. Neurobiol Dis 2005; 19:312-322.
65. SWERDLOW RH, PARKS JK, CASSARINO DS et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 1997; 49:918-925.
66. BARACCA A, BAROGI S, CARELLI V, LENAZ G, SOLAINI G. Catalytic activities of mitochondrial ATP synthase in patients with mitochondrial DNA T8993G mutation in the ATPase 6 gene encoding subunit a. J Biol Chem 2000; 275:4177-4182.
67. MATTIAZZI M, VIJAYVERGIYA C, GAJEWSKI CD et al. The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved by antioxidants. Hum Mol Genet 2004; 13:869-879.
68. GALANO A, TAN DX, REITER RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51:1-16.
69. VENEGAS C, GARCIA JA, ESCAMES G et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 2012; 52:217-227.
70. JOU MJ, JOU SB, CHEN HM, LIN CH, PENG TI. Critical role of mitochondrial reactive oxygen species formation in visible laser irradiation-induced apoptosis in rat brain astrocytes (RBA-1). J Biomed Sci 2002; 9:507-516.
71. JOU MJ, JOU SB, GUO MJ, WU HY, PENG TI. Mitochondrial reactive oxygen species generation and calcium increase induced by visible light in astrocytes. Ann N Y Acad Sci 2004; 1011:45-56.
72. JOU MJ, PENG TI, REITER RJ, JOU SB, WU HY, WEN ST. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 2004; 37:55-70.
73. MOSMANN T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
74. VILLANI G, ATTARDI G. In vivo measurements of respiration control by cytochrome c oxidase and in situ analysis of oxidative phosphorylation. Methods Cell Biol 2001; 65:119-131.
75. BEZPROZVANNY I. Calcium signaling and neurodegenerative diseases. Trends Mol Med 2009; 15:89-100.
76. BOJARSKI L, HERMS J, KUZNICKI J. Calcium dysregulation in Alzheimer's disease. Neurochem Int 2008; 52:621-633.
77. LAFERLA FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 2002; 3:862-872.
78. MATTSON MP, CHAN SL. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 2003; 34:385-397.
79. YU JT, CHANG RC, TAN L. Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog Neurobiol 2009; 89:240-255.
80. HUNG CH, HO YS, CHANG RC. Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease. Ageing Res Rev 2010; 9:447-456.
81. MATTSON MP, CHENG B, DAVIS D, BRYANT K, LIEBERBURG I, RYDEL RE. Beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12:376-389.
82. ZHU YJ, LIN H, LAL R. Fresh and nonfibrillar amyloid beta protein (1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for AbetaP-channel-mediated cellular toxicity. FASEB J 2000; 14:1244-1254.
83. GUNTER TE, YULE DI, GUNTER KK, ELISEEV RA, SALTER JD. Calcium and mitochondria. FEBS Lett 2004; 567:96-102.
84. FERREIRA IL, BAJOUCO LM, MOTA SI, AUBERSON YP, OLIVEIRA CR, REGO AC. Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-D-aspartate receptors in cortical cultures. Cell Calcium 2012; 51:95-106.
85. 2+ storage capacity of rat brain mitochondria declines during the postnatal development without change in ROS production capacity. Antioxid Redox Signal 2007; 9:191-199.
86. GRIFFITHS EJ. Mitochondria and heart disease. Adv Exp Med Biol 2012; 942:249-267.
87. PENG TI, YU PR, CHEN JY et al. Visualizing common deletion of mitochondrial DNA-augmented mitochondrial reactive oxygen species generation and apoptosis upon oxidative stress. Biochim Biophys Acta 2006; 1762:241-255.
88. CHAN DC. Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol 2006; 22:79-99.
89. CHEN H, CHAN DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009; 18:R169-R176.
90. JOU MJ. Pathophysiological and pharmacological implications of mitochondria-targeted reactive oxygen species generation in astrocytes. Adv Drug Deliv Rev 2008; 60:1512-1526.
91. ACIN-PEREZ R, FERNANDEZ-SILVA P, PELEATO ML, PEREZ-MARTOS A, ENRIQUEZ JA. Respiratory active mitochondrial supercomplexes. Mol Cell 2008; 32:529-539.
92. SANMARTIN CD, ADASME T, HIDALGO C, PAULA-LIMA AC. The antioxidant N-acetylcysteine prevents the mitochondrial fragmentation induced by soluble amyloid-beta peptide oligomers. Neurodegener Dis 2012; 10:34-37.
93. ZAMZAMI N, MARCHETTI P, CASTEDO M et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995; 182:367-377.
94. ZOROV DB, FILBURN CR, KLOTZ LO, ZWEIER JL, SOLLOTT SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 2000; 192:1001-1014.
95. ZOROV DB, JUHASZOVA M, SOLLOTT SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta 2006; 1757:509-517.